Sarcoma & GIST
Conference Coverage
Analysis of early onset cancers suggests need for genetic testing
The prevalence of germline mutations was significantly higher in patients with early onset cancers than in those with young adult cancers.
News from the FDA/CDC
FDA approves new indications for pembrolizumab
Feature
Can an app guide cancer treatment decisions during the pandemic?
Conference Coverage
Three years of imatinib may halve death rate in GIST
Receiving imatinib for 3 years rather than 1 year improved overall survival by 50% and recurrence-free survival by 30%.
Feature
‘A good and peaceful death’: Cancer hospice during the pandemic
Conference Coverage
Germline testing in advanced cancer can lead to targeted treatment
In a study of nearly 12,000 cancer patients, 7%-9% of patients had targetable germline alterations.
News
Oncologists’ income and satisfaction are up
News from the FDA/CDC
FDA approves pomalidomide for Kaposi sarcoma
Conference Coverage
Video coaching may relieve anxiety and distress for long-distance cancer caregivers
Conference Coverage
ASCO goes ahead online, as conference center is used as hospital
From the Journals
Excess cancer deaths predicted as care is disrupted by COVID-19